Mr. John Morgan reports

MC PARTNERS INC. FILES ITS FILING STATEMENT IN CONNECTION WITH ITS PROPOSED QUALIFYING TRANSACTION

Following MC Partners Inc.'s receipt of the exchange's conditional acceptance of the company's previously announced proposed qualifying transaction with bioMmune Technologies Inc., MC Partners has now filed its filing statement in relation to the proposed transaction on SEDAR, and a copy of the same is available under the company's profile at SEDAR.

Completion of the proposed transaction is subject to fulfilling all conditions of the exchange, including but not limited to submission by the sponsor and receipt by the exchange of a satisfactory sponsor report and completion of a concurrent non-brokered private placement of 10 million units of the company at a price of 15 cents per unit for gross proceeds of $1.5-million. Each unit will consist of one common share of the company and one common share purchase warrant of the company. Each whole warrant will entitle the holder to purchase one additional common share of the company at a price of 25 cents for a period of 12 months from the completion of the financing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the company may exercise once the units are free of resale restrictions and if the company's shares are trading at or above a volume-weighted average price of 40 cents for more than 20 trading consecutive days, the warrants will expire upon 30 days from the date the company provides notice in writing to the warrantholders by a news release.

Upon completion of the proposed transaction, the company will change its name to reflect the nature and character of the business of bioMmune, with the resulting issuer trading as a Tier 2 research and development issuer on the exchange.

Trading in the shares of the company will remain halted until such time as the proposed transaction is completed.

We seek Safe Harbor.